Sevoflurane In Acute Myocardial Infarction (SIAMI)
Ischemic postconditioning can reduce myocardial injury following myocardial infarction.
A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflurane during primary percutaneous coronary intervention (PCI) will reduce infarct size.
|Acute Myocardial Infarction||Drug: Oxygen + Sevoflurane Drug: Oxygen (placebo)||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Sevoflurane Sedation During Primary Percutaneous Coronary Intervention.|
- Infarct size by area under the curve of cardiac markers. [ Time Frame: 3 days ]
- Left ventricular function. [ Time Frame: Six month ]
- ST segment elevation resolution [ Time Frame: 90 minutes ]
- TIMI flow [ Time Frame: 60 minutes ]
- Renal function [ Time Frame: 48 hours ]
- CRP [ Time Frame: 24 hours ]
- Patient satisfaction [ Time Frame: 1 hour ]
|Study Start Date:||May 2009|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Active Comparator: 1
Drug: Oxygen + Sevoflurane
Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
Placebo Comparator: 2
Drug: Oxygen (placebo)
Control will receive oxygen only.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00971607
|London Health Sceinces Centre|
|London, Ontario, Canada, N6A5A5|
|Principal Investigator:||Shahar Lavi, MD||Lawson Health Research Institute|